AG
CYTK icon

Aperio Group’s Cytokinetics CYTK Stock Holding History

Aperio Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$562K Buy
27,036
+2,199
+9% +$40.2K ﹤0.01% 1909
2020
Q3 		$538K Buy
24,837
+3,571
+17% +$83.5K ﹤0.01% 1774
2020
Q2 		$501K Buy
21,266
+2,593
+14% +$48.6K ﹤0.01% 1783
2020
Q1 		$220K Buy
18,673
+2,727
+17% +$34.8K ﹤0.01% 2060
2019
Q4 		$169K Sell
15,946
-7,306
-31% -$75K ﹤0.01% 2219
2019
Q3 		$265K Buy
23,252
+6,981
+43% +$87.6K ﹤0.01% 2068
2019
Q2 		$183K Buy
+16,271
New +$157K ﹤0.01% 2211

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aperio Group's CYTK Position: Q4 2020 in Review

Aperio Group increased its Cytokinetics (CYTK) stake by 8.9% in Q4 2020, buying an estimated $40.2K and bringing the position to 27,036 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #1909.

Aperio Group first reported a position in CYTK in Q2 2019 and has held it in 7 quarters since. 178 funds tracked by Wall St. Rank hold CYTK as of Q4 2020.

  • Aperio Group held 27,036 shares of Cytokinetics worth $562K as of Q4 2020.
  • Aperio Group bought 2,199 Cytokinetics shares in Q4 2020, an estimated $40.2K.
  • Cytokinetics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1909 holding.
  • Aperio Group first reported a position in Cytokinetics in Q2 2019 and has held it in 7 quarters since.
  • 178 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.